The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
LeeJL, KimSC, KimJH, Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012;152(5):851–862.
2.
SchoppmeyerK, MietheS, WiedmannM, Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: A phase I/II trial. Am J Clin Oncol. 2006;29(6):576–582.
3.
KnoxJJ, HedleyD, OzaA, Combining gemcitabine and capecitabine in patients with advanced biliary cancer: A phase II trial. J Clin Oncol. 2005;23(10):2332–2338.
4.
ChoJY, PaikYH, ChangYS, Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer. 2005;104(12):2753–2758.
5.
RiechelmannRP, TownsleyCA, ChinSN, Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer. 2007;110(6):1307–1312.
6.
KoeberleD, SalettiP, BornerM, Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: A multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008;26(22):3702–3708.
7.
KoAH, EspinozaAM, JonesKA, Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: A dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012;35(5):411–417.
8.
ChoJY, NamJS, ParkMS, A phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma. Yonsei Med J.2005;46(4):526–531.
9.
IyerRV, GibbsJ, KuvshinoffB, A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: A single-institution prospective study. Ann Surg Oncol. 2007;14(11):3202–3209.
10.
ScheithauerW, SchüllB, Ulrich-PurH, Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial. Ann Oncol. 2003;14(1):97–104.
11.
HessV, SalzbergM, BornerM, Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial. J Clin Oncol. 2003;21(1):66–68.
12.
StathopoulosGP, SyrigosK, PolyzosA, Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study. Ann Oncol. 2004;15(2):224–229.
13.
ParkBB, ParkJO, LeeHR, A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2007;60(4):489–494.
14.
HerrmannR, BodokyG, RuhstallerT, Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212–2217.
15.
BernhardJ, DietrichD, ScheithauerW, Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: A randomized multicenter phase III clinical trial–SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol.2008;26(22):3695–3701.
16.
SongHS, DoYR, ChangHM, A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2008;62(5):763–768.
17.
BoeckS, HoehlerT, SeipeltG, Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): Final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol. 2008;19(2):340–347.
18.
MichaelM, PriceT, NganSY, A phase I trial of capecitabine+gemcitabine with radical radiation for locally advanced pancreatic cancer. Br J Cancer. 2009;100(1):37–43.
19.
CunninghamD, ChauI, StockenDD, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27(33):5513–5518.
20.
JeonEK, WonHS, KoYH, Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. J Cancer Res Clin Oncol. 2012;138(10): 1625–1630.
GelingO, EichlerHG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005;23(6):1289–1294.
28.
TerreyJP, AaproMS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996;8:281–288.
29.
CarmichaelJ, KeizerHJ, CupissolD, MilliezJ, ScheidelP, SchindlerAE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998;9(5):381–385.
30.
de WitR, de BoerAC, vd LindenGH, StoterG, SparreboomA, VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19;85(8):1099–1101.
31.
SmithIE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993;119(6):350–354.
32.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994;2(3):177–183.
33.
SmithTJ, KhatcheressianJ, LymanGH, 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205.
MarounJA, AnthonyLB, BlaisN, Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: A consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol. 2007;14(1):13–20.
36.
BensonAB, AjaniJA, CatalanoRB, Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol2004;22(14):2918–2926.
37.
BoyiadzisMM, LebowitzPF, FrameJN, FojoT.Hematology-Oncology Therapy. New York: McGraw-Hill; 2007:570–578.
38.
KintzelPE, DorrRT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33–64.
39.
KingPD. PerryMC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162–176.
